Discover TCR mimic antibodies that Target Previously “Undruggable” Intracellular Proteins with Keyway™ TCR
Webinar Overview:
Unlock access to intracellular protein targets and maximize TCRm/TCR-based therapeutic antibody discovery with this presentation by Dr. Dongxing Zha that reveals how Alloy’s proprietary
Keyway™ TCRm Discovery Platform and expertise can:
- Overcome challenges to intracellular protein-targeted drug discovery: Learn how the Keyway™ TCRm Discovery Platform identifies TCR mimic (TCRm) antibodies that target intracellular antigens presented on cell surface MHC molecules (pMHC complexes) with high
- Identify highly-specific functional TCRm leads: Discover Alloy’s proprietary specificity screening and high-quality pMHC complex antigen production capabilities
- Accelerate immunotherapy development: Unleash the potential for development of antibody-like bispecific formats for simultaneous effector cell engagement and target engagement.
Webinar sample above. To access the full video content, fill out the form below.
About the Speaker:
Dongxing Zha, PhD
CEO of KeywayM TCR Discovery,
CTO of TCR Discovery and Engineering
Alloy Therapeutics
Dr. Dongxing Zha is CEO of Keyway TCR Discovery at Alloy Therapeutics. He previously led the ORBIT platform at MD Anderson Cancer Center, a Moon Shots platform focused on biologic and cell-based therapies, where he oversaw the team that advanced the first TCRm to the clinic for the treatment of various hematological malignancies. Dr. Zha received his PhD in microbiology from Huazhong Agricultural
